Skip to content
10-Q

Quarterly Report

REGENEREX PHARMA, INC. RGPX

0001472375-25-000013

← back to feed
Filed
Feb 7, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Feb 7, 2025 278.47M sh
Operating Cash Flow Q3 2024 · Dec 31, 2024 −$340.65K
Operating Cash Flow Q3 2024 · Dec 31, 2023 −$393.11K
Cash And Equivalents Q3 2024 · Dec 31, 2024 $338
Cash And Equivalents Q3 2024 · Mar 31, 2024 $372
Stockholders Equity Q3 2024 · Dec 31, 2024 −$5.05M
Stockholders Equity Q3 2024 · Sep 30, 2024 −$4.76M
Stockholders Equity Q3 2024 · Mar 31, 2024 −$4.06M
Stockholders Equity Q3 2024 · Dec 31, 2023 −$3.88M
Stockholders Equity Q3 2024 · Sep 30, 2023 −$3.63M
Stockholders Equity Q3 2024 · Mar 31, 2023 −$1.12M
Current Liabilities Q3 2024 · Dec 31, 2024 $5.16M
Current Liabilities Q3 2024 · Mar 31, 2024 $3.84M
Total Liabilities Q3 2024 · Dec 31, 2024 $5.7M
Total Liabilities Q3 2024 · Mar 31, 2024 $4.83M
Current Assets Q3 2024 · Dec 31, 2024 $988
Current Assets Q3 2024 · Mar 31, 2024 $2.91K
Total Assets Q3 2024 · Dec 31, 2024 $646.86K
Total Assets Q3 2024 · Mar 31, 2024 $766.68K
Rd Expense Q3 2024 · Dec 31, 2024 $17.38K
Rd Expense Q3 2024 · Dec 31, 2024 $17.38K
Rd Expense Q3 2024 · Dec 31, 2023 $2.4M
Net Income Q3 2024 · Dec 31, 2024 −$314.53K
Net Income Q3 2024 · Dec 31, 2024 −$1.12M
Net Income Q3 2024 · Sep 30, 2024 −$802.13K
Net Income Q3 2024 · Dec 31, 2023 −$263.98K
Net Income Q3 2024 · Dec 31, 2023 −$3.25M
Net Income Q3 2024 · Sep 30, 2023 −$2.99M
Operating Income Q3 2024 · Dec 31, 2024 −$311.51K
Operating Income Q3 2024 · Dec 31, 2024 −$824.17K
Operating Income Q3 2024 · Dec 31, 2023 −$239.38K
Operating Income Q3 2024 · Dec 31, 2023 −$3.19M
Long Term Debt Q3 2024 · Mar 31, 2024 $184.23K